Sentiment from Key Opinion Leaders regarding ADAURA Trial presented at #ASCO23

Total Impressions 910,582

ADAURA KOL Sentiment

 -100100Negativ

Key Opinion Leader Sentiment Analysis of ADAURA Trial

Doctor Name Sentiment Comment
Stephen V Liu, MD
POSITIVE
Highlight of the #IULungSymposium is getting to hear Dr. Larry Einhorn discuss the field. Poses critical questions for the field. One of the great speakers in thoracic oncology. #LCSM https://t.co/BrpOk63tLy
NathanPennel2
Nathan A. Pennell MD, PhD, FASCO
POSITIVE
Thanks to @VivekSubbiah for giving @JackWestMD and I a chance to channel our debates into surprising consensus! #LCSM Lessons from ADAURA: Can we improve on a positive trial? - West and Pennell - Cancer https://t.co/3h47aR03gd
Jonathan Spicer MD PhD
POSITIVE
#ALINA, #ADAURA and #KN671 were all smiles today @myESMO #ESMO23! Love these guys! https://t.co/094rK9iW1B
Charu Aggarwal, MD, MPH, FASCO
POSITIVE
@christine_lovly @Alexmenter @ASCO @OncoAlert @OncBrothers @JackWestMD I see that using the word “cure” makes oncologists uncomfortable. The curves above show that we are undeniably improving survival. https://t.co/xWdKhfa03s
Christine Lovly, MD, PhD
POSITIVE
@Alexmenter @CharuAggarwalMD @ASCO @OncoAlert @OncBrothers Agree! I am very enthusiastic about the ADAURA data. But can we truly say “cure” with the available data? @JackWestMD
Dr Halmos
Balazs Halmos, MD
POSITIVE
#ASCO23 ADAURAble results! How it started How it is going 👇 👇 https://t.co/WuvwSG6qn6
H. Jack West, MD
NEUTRAL
🚨That also doesn't factor in that the patients directed to adjuvant chemo almost certainly had higher risk disease, while those who didn't were enriched for more favorable disease features. Know that if you don't recommend adjuvant chemo, you're undertreating. https://t.co/73QGsmEhzd
Jeff Ryckman, MD
NEGATIVE
@MassimoDiMaio75 Love how the response is that "data suggest that the greatest overall survival benefit is achieved with the use of adjuvant osimertinib, as supported by the results of the ADAURA and FLAURA trials" ...as if there were a trial of salvage vs. adjuvant osimertinib?? The prevailing… https://t.co/vgdEtbAKbo
Vinay Prasad MD MPH
NEGATIVE
#adaura has dozens and dozens of authors. Fda onc hundreds of employees. Not a single one of them fought for the control arm patients. Now control on patients have to litigate. I don't disagree, but it is amazing. #asco23 https://t.co/Qna3mYVfiW
Vladmir C. Cordeiro de Lima, MD, PhD
NEGATIVE
@JackWestMD 👍When you're about to present a potentially paradigm-shifting study, you better make all effort to leave no room for questioning. In this particular case: no PET / brain RM before osi initiation, adjv chemo at invest discretion, OS as 2nd endpoint, no mandatory crossover at PD.
H. Jack West, MD
NEGATIVE
Helpful background. But AZ promoted osi as clear optimal 1L SOC for relapsed/adv EGFRm+ NSCLC since 2017 presentation of ADAURA, & osi was longstanding 1L SOC in US & much of ROW long before 4/2020. IMO, disngenuous to say that while not yet offering to pts w/relapse in ctrl arm. https://t.co/MavabLw2mU